Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics.
about
Dinosaurs and ancient civilizations: reflections on the treatment of cancerMagnetic resonance elastography (MRE) in cancer: Technique, analysis, and applicationsThe tumor microenvironment and strategies to improve drug distributionEstimation of Tumor Interstitial Fluid Pressure (TIFP) NoninvasivelyTumor blood flow differs between mouse strains: consequences for vasoresponse to photodynamic therapyPhase-change contrast agents for imaging and therapy.Subharmonic aided pressure estimation for monitoring interstitial fluid pressure in tumours--in vitro and in vivo proof of conceptDecafluorobutane as a phase-change contrast agent for low-energy extravascular ultrasonic imaging.Tumour T1 changes in vivo are highly predictive of response to chemotherapy and reflect the number of viable tumour cells--a preclinical MR study in mice.Mild elevation of body temperature reduces tumor interstitial fluid pressure and hypoxia and enhances efficacy of radiotherapy in murine tumor modelsAnti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PETHigh interstitial fluid pressure is associated with tumor-line specific vascular abnormalities in human melanoma xenografts.Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study.The interconnectedness of cancer cell signaling.The War on Cancer rages on.MRI & MRS assessment of the role of the tumour microenvironment in response to therapy.Magnetically vectored platforms for the targeted delivery of therapeutics to tumors: history and current status.Intratumoral gene therapy versus intravenous gene therapy for distant metastasis control with 2-diethylaminoethyl-dextran methyl methacrylate copolymer non-viral vector-p53.Recent advances of thermally responsive nanogels for cancer therapy.Monitoring Neoadjuvant Chemotherapy for Breast Cancer by Using Three-dimensional Subharmonic Aided Pressure Estimation and Imaging with US Contrast Agents: Preliminary Experience.Tumor interstitial fluid and gastric cancer metastasis: an experimental study to verify the hypothesis of "tumor-phlegm microenvironment".Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma.The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems.Phenomenological model of interstitial fluid pressure in a solid tumor.Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.Mathematical modeling of intraperitoneal drug delivery: simulation of drug distribution in a single tumor nodule.Reducing endothelial NOS activation and interstitial fluid pressure with n-3 PUFA offset tumor chemoresistance.Subharmonic-Aided Pressure Estimation for Monitoring Interstitial Fluid Pressure in Tumors: Calibration and Treatment with Paclitaxel in Breast Cancer Xenografts.E. coli Nissle 1917-Derived Minicells for Targeted Delivery of Chemotherapeutic Drug to Hypoxic Regions for Cancer Therapy.
P2860
Q24628746-77C6EF11-AD06-415F-8541-177BB3A45B57Q28081554-7EC391AC-8912-4B93-B3F5-3E507BC77C5DQ28384148-7AD0D288-0FF3-4233-8CAD-4F5EA3E736A1Q28553190-8123E2B5-5D04-4B6C-BB1F-C1D2E82A5A77Q28729877-38254B81-BBA8-45A9-A19A-49524F884C49Q30373053-9DDC5E4B-B79A-4932-98B0-9EC42404F8EEQ30404198-C1510788-2327-4D7A-B870-7BFF055EF48AQ30410631-3464CD1D-BDAD-4E51-986D-77A053135B75Q30757279-AEECD1C2-FD71-464A-8B9D-CDC8F7F27DB9Q33879424-EB699BD3-B1F7-4FA7-9E7B-2EFE5D490F5AQ34041370-91E650EA-8265-427E-BFFA-115F75441128Q34328523-D3CC8EE6-F3EE-4FD5-9B97-7104BC2A499BQ34852414-BAD21282-0098-4B9A-9EB7-F095C0E11BB2Q35669733-7CE79F47-ACE7-45A1-B6EC-76121C750DE4Q37478602-4A7B5CA9-D1E1-45CF-BE8E-D790FD618CFDQ37875004-AEC20992-A988-4AE2-BADC-FEA7CCBC4A79Q37984489-BC7A2593-1953-47D8-873F-01CCE36B1520Q38451785-9CB7BF03-89D6-497B-9311-69353C0CFDE8Q38610494-97317FC0-62FD-4D96-B964-0260CD59CE4FQ38807259-5B5C8A47-FF70-45EF-8DE1-521FBFD84142Q39355514-F75AAE76-83AD-47FD-ADB1-055C49B414B8Q39698452-95FB46CB-577B-4232-8FF0-C43D9C409D61Q40793421-F56E25FD-479B-47F2-B141-3E20B2535A1BQ41828751-5991849A-2501-4EBD-B7AE-7975F08D68E0Q42444375-0EEA58C2-F0C0-43E4-9D2E-BC8D1D90442FQ47119535-4732F91C-E835-43E6-8AAE-DD22D8C526C9Q47978622-22CF74DA-44C5-4E66-AD1B-BE9AF18FEA3BQ50265012-F0A0E185-6B25-4222-88D9-914DADC27266Q50905947-37C858F3-155B-47B0-9C6C-D60F867D6F69Q52647653-0CDDC530-8EB9-4360-A1CA-D3DCC0776F2E
P2860
Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tumor interstitial fluid press ...... r for anticancer therapeutics.
@en
Tumor interstitial fluid press ...... r for anticancer therapeutics.
@nl
type
label
Tumor interstitial fluid press ...... r for anticancer therapeutics.
@en
Tumor interstitial fluid press ...... r for anticancer therapeutics.
@nl
prefLabel
Tumor interstitial fluid press ...... r for anticancer therapeutics.
@en
Tumor interstitial fluid press ...... r for anticancer therapeutics.
@nl
P2093
P2860
P356
P1433
P1476
Tumor interstitial fluid press ...... r for anticancer therapeutics.
@en
P2093
Mike M Becquet
Paul Mj McSheehy
Peter R Allegrini
Stephane Ferretti
P2860
P304
P356
10.1593/NEO.09554
P577
2009-09-01T00:00:00Z